The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

被引：0
作者：
Binyu, W. [1 ]
Yao, F. [2 ]
Mengxia, C. [1 ]
Shan, P. [2 ]
Giancarlo, M. [3 ]
Junlong, Z. [1 ]
Shiwei, Z. [1 ]
Hongqian, G. [1 ]
Xuefeng, Q. [1 ]
机构：
[1] Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Urol, Nanjing, Peoples R China
[2] Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Pathol, Nanjing, Peoples R China
[3] San Giovanni Battista Hosp, Dept Urol, Turin, Italy
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0290
引用
收藏
页码：S1084 / S1084
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer
    Eapen, Renu S.
    Williams, Scott G.
    Macdonald, Sean
    Keam, Simon P.
    Lawrentschuk, Nathan
    Au, Lewis
    Hofman, Michael S.
    Murphy, Declan G.
    Neeson, Paul J.
    NATURE REVIEWS UROLOGY, 2024, 21 (11) : 676 - 686
  • [32] Cribriform/Intraductal Carcinoma, a Candidate Predictor of Response to Neoadjuvant Treatment with Novel Androgen Inhibitors in Localized High Risk Prostate Cancer
    Troncoso, Patricia
    Li-Ning-Tapia, Elsa
    Davis, John W.
    Wang, Xuemei
    Prokhorova, Ina
    Pisters, Louis
    Pettaway, Curtis
    Efstathiou, Eleni
    LABORATORY INVESTIGATION, 2017, 97 : 266A - 266A
  • [33] Tissue biomarkers in patients with high-risk prostate cancer treated with neoadjuvant chemohormonal therapy
    Narita, Shintaro
    Nara, Taketoshi
    Chiba, Syuji
    Kanda, Sohei
    Numakura, Kazuyuki
    Saito, Mitsuru
    Inoue, Takamitsu
    Huang, Mingguo
    Nanjo, Hiroshi
    Habuchi, Tomonori
    CANCER SCIENCE, 2018, 109 : 1023 - 1023
  • [34] THE RISK OF PROSTATE CANCER DEATH FOR ELDERLY MEN WITH TREATED HIGH-RISK PROSTATE CANCER AND NO OR CORRECTED CARDIOVASCULAR DISEASE
    Hoffman, Karen E.
    Chen, Ming-Hui
    Moran, Brian J.
    Braccioforte, Michelle H.
    Dosoretz, Daniel
    Salenius, Sharon
    Katin, Michael
    Ross, Rudi
    D'Amico, Anthony V.
    JOURNAL OF UROLOGY, 2009, 181 (04) : 207 - 207
  • [35] Proton Therapy in the Management of High-Risk Prostate Cancer
    Bryant, C. M.
    Henderson, R. H.
    Hoppe, B. S.
    Mendenhall, W. M.
    Nichols, R.
    Su, Z.
    Li, Z.
    Williams, C. R.
    Morris, C. G.
    Mendenhall, N. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S420 - S420
  • [36] High-Risk Prostate Cancer: Local Therapy Matters
    Liss, Adam L.
    Hamstra, Daniel A.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (06) : 14 - 19
  • [37] Oncological results of neoadjuvant chemohormonal therapy in patients with high and very high-risk prostate cancer
    Berkut, M., V
    Artemjeva, A. S.
    Reva, S. A.
    Tolmachev, S. S.
    Petrov, S. B.
    Nosov, A. K.
    ONKOUROLOGIYA, 2020, 16 (01): : 54 - 63
  • [38] Prostate Cancer Screening Among High-Risk Black Men
    Roberts, Lisa R.
    Wilson, Colwick M.
    Stiel, Laura
    Casiano, Carlos A.
    Montgomery, Susanne B.
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2018, 14 (09): : 677 - +
  • [39] Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer
    Bratt, Ola
    Folkvaljon, Yasin
    Eriksson, Marie Hjalm
    Akre, Olof
    Carlsson, Stefan
    Drevin, Linda
    Lissbrant, Ingela Franck
    Makarov, Danil
    Loeb, Stacy
    Stattin, Par
    EUROPEAN UROLOGY, 2015, 68 (01) : 53 - 58
  • [40] Androgen Deprivation Therapy in High-Risk Prostate Cancer
    Buyyounouski, Mark K.
    ONCOLOGY-NEW YORK, 2010, 24 (09): : 806 - 809
12345